IC
CYTK icon

Ikarian Capital’s Cytokinetics CYTK Stock Holding History

Ikarian Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.3M Buy
+550,500
New +$35M 2.95% 7
2024
Q2 		– Sell
-100,000
Closed -$7.01M – 129
2024
Q1 		$7.01M Buy
100,000
+96,500
+2,757% +$7.46M 0.77% 44
2023
Q4 		$292K Buy
3,500
+1,465
+72% +$53K 0.03% 122
2023
Q3 		$6M Buy
+2,035
New +$67.8K 0.72% 41
2020
Q4 		– Sell
-320,000
Closed -$6.93M – 241
2020
Q3 		$6.93M Buy
+320,000
New +$7.49M 0.5% 52
2020
Q2 		– Sell
-384,400
Closed -$4.53M – 183
2020
Q1 		$4.53M Buy
+384,400
New +$4.9M 0.34% 67

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ikarian Capital's CYTK Position: Q1 2026 in Review

Ikarian Capital increased its Cytokinetics (CYTK) stake by 64% in Q1 2026, buying an estimated $7.05M and bringing the position to 283,572 shares worth $18.7M. The position accounts for 1.52% of the portfolio, ranked #16.

Ikarian Capital first reported a position in CYTK in Q3 2020 and has held it in 15 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Ikarian Capital held 283,572 shares of Cytokinetics worth $18.7M as of Q1 2026.
  • Ikarian Capital bought 110,900 Cytokinetics shares in Q1 2026, an estimated $7.05M.
  • Cytokinetics made up 1.52% of Ikarian Capital's portfolio in Q1 2026, its #16 holding.
  • Ikarian Capital first reported a position in Cytokinetics in Q3 2020 and has held it in 15 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.